|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
1,095,971,000 |
Market
Cap: |
18.43(B) |
Last
Volume: |
6,991,309 |
Avg
Vol: |
10,613,475 |
52
Week Range: |
$7.31 - $17.09 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Teva Pharmaceutical Industries is a pharmaceutical company. Co. operates through three segments: North America, which includes the U.S. and Canada; Europe, which includes the European Union and certain other European countries; and International Markets, which includes all countries in which Co. operates other than those in Co.'s North America and Europe segments. Co.'s products include: AUSTEDO; AJOVY (anti calcitonin gene-related peptide); COPAXONE; BENDEKA and TREANDA; ProAir HFA; ProAir RespiClick; QVAR; QVAR RediHaler; ProAir Digihaler; ArmonAir Digihaler; AirDuo Digihaler; BRALTUS®; CINQAIR/CINQAERO; and AirDuo RespiClick.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
43,354 |
720,697 |
810,545 |
1,346,844 |
Total Sell Value |
$725,601 |
$9,700,206 |
$10,499,443 |
$15,688,359 |
Total People Sold |
2 |
8 |
8 |
10 |
Total Sell Transactions |
3 |
17 |
20 |
34 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Dethlefs Sven |
EVP, North America Commercial |
|
2022-02-28 |
4 |
AS |
$8.14 |
$39,587 |
D/D |
(4,862) |
99,457 |
|
-8% |
|
Dethlefs Sven |
EVP, North America Commercial |
|
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,346 |
104,319 |
|
- |
|
Daniell Richard |
Exec. VP, European Commercial |
|
2022-02-28 |
4 |
AS |
$8.14 |
$167,713 |
D/D |
(20,598) |
20,280 |
|
-8% |
|
Daniell Richard |
Exec. VP, European Commercial |
|
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,598 |
40,878 |
|
- |
|
Weiss Amir |
Chief Accounting Officer |
|
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,219 |
17,610 |
|
- |
|
Drape Eric |
Executive VP Global Operations |
|
2022-02-28 |
4 |
AS |
$8.14 |
$79,769 |
D/D |
(9,797) |
45,830 |
|
-8% |
|
Drape Eric |
Executive VP Global Operations |
|
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,514 |
55,627 |
|
- |
|
Sabag Mark |
EVP, International Markets |
|
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,598 |
94,603 |
|
- |
|
Stark David Matthew |
Exec. VP Chief Legal Officer |
|
2022-02-28 |
4 |
AS |
$8.14 |
$52,533 |
D/D |
(6,452) |
21,380 |
|
-8% |
|
Stark David Matthew |
Exec. VP Chief Legal Officer |
|
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,430 |
27,832 |
|
- |
|
Schultz Kare |
President and CEO |
|
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
65,047 |
1,132,496 |
|
- |
|
Fridriksdottir Hafrun |
Executive VP, Global R&D |
|
2022-02-28 |
4 |
AS |
$8.14 |
$61,799 |
D/D |
(7,590) |
65,509 |
|
-8% |
|
Fridriksdottir Hafrun |
Executive VP, Global R&D |
|
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,682 |
73,099 |
|
- |
|
Inbar Galia |
See Remarks |
|
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,828 |
9,656 |
|
- |
|
Kalif Eliyahu Sharon |
EVP, Chief Financial Officer |
|
2022-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,629 |
25,059 |
|
- |
|
Stark David Matthew |
Exec. VP Chief Legal Officer |
|
2022-02-09 |
4 |
AS |
$9.06 |
$55,358 |
D/D |
(6,110) |
9,402 |
|
-15% |
|
Stark David Matthew |
Exec. VP Chief Legal Officer |
|
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,538 |
15,512 |
|
- |
|
Dethlefs Sven |
EVP, North America Commercial |
|
2022-02-09 |
4 |
AS |
$9.06 |
$37,491 |
D/D |
(4,138) |
86,973 |
|
-15% |
|
Dethlefs Sven |
EVP, North America Commercial |
|
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,135 |
91,111 |
|
- |
|
Drape Eric |
Executive VP Global Operations |
|
2022-02-09 |
4 |
AS |
$9.06 |
$32,464 |
D/D |
(3,583) |
36,113 |
|
-15% |
|
Drape Eric |
Executive VP Global Operations |
|
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,568 |
39,696 |
|
- |
|
Fridriksdottir Hafrun |
Executive VP, Global R&D |
|
2022-02-09 |
4 |
AS |
$9.06 |
$55,412 |
D/D |
(6,116) |
51,417 |
|
-15% |
|
Fridriksdottir Hafrun |
Executive VP, Global R&D |
|
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,121 |
57,533 |
|
- |
|
Sabag Mark |
EVP, International Markets |
|
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,523 |
74,005 |
|
- |
|
Schultz Kare |
President and CEO |
|
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,867 |
1,067,449 |
|
- |
|
524 Records found
|
|
Page 7 of 21 |
|
|